Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims’ new strategy to launch a copycat pill but also goes after shots that mimic Weg ...

Core Viewpoint - Hims & Hers Health Inc. has decided to stop selling its copycat version of Wegovy's weight-loss pill following regulatory scrutiny from the FDA and pressure from Novo Nordisk [1][3]. Group 1: Company Actions - Hims announced plans to launch a cheaper version of Novo Nordisk's Wegovy weight-loss pill but has since halted sales after discussions with stakeholders [1][2]. - The FDA is investigating Hims for potential violations of federal law regarding the sale of copycat weight-loss treatments [3]. Group 2: Industry Context - The FDA has faced criticism from major pharmaceutical companies like Novo and Eli Lilly for not adequately addressing the proliferation of cheaper, compounded weight-loss drugs [4]. - Hims has previously experienced friction with Novo, including a failed partnership over discounted weight-loss shots due to compounding issues [5]. Group 3: Leadership Statements - Hims CEO Andrew Dudum expressed a strong stance against complying with pharmaceutical companies' demands regarding copycat weight-loss drugs, indicating a commitment to their business strategy [6].

Hims & Hers Health Inc. said it will stop selling its knockoff weight-loss pill just days after initially offering it, following an announcement by federal regulators that they were launching an investigation into the telehealth company. https://t.co/HFunQIAQAj ...

Core Viewpoint - Hims & Hers Health Inc. is in preliminary talks with Novo Nordisk A/S to potentially sell its upcoming obesity pill on its telehealth platform, which could enhance revenue opportunities for the company, although no definitive agreement has been reached yet [1][2]. Group 1: Financial Performance - Hims reported $599 million in revenue for the quarter, exceeding Wall Street's average estimates [2]. - The company has adjusted its sales guidance for the year to a maximum of $2.36 billion, slightly below the previous forecast of $2.4 billion [4]. Group 2: Market Dynamics - Hims has shifted its business focus towards weight-loss drugs, initially offering alternatives during shortages of Novo and Eli Lilly's products, but is now facing regulatory scrutiny on copycat drugs, impacting its sales [3]. - The previous partnership with Novo ended in June due to accusations of deceptive marketing related to copycat versions of Novo's Wegovy [2][3]. Group 3: Analyst Insights - Analysts suggest that a partnership with Novo could alleviate market pressures on Hims' ability to sell weight-loss drugs [4]. - Investor expectations had already adjusted downwards prior to earnings, making the softer fourth-quarter guidance less surprising, with ongoing debates about growth headwinds and new product launches [5].

Core Viewpoint - Federal health officials are targeting telehealth companies for promoting unofficial versions of prescription drugs, particularly weight loss medications, as part of a crackdown on pharmaceutical advertising initiated by the Trump administration [1][6]. Regulatory Actions - The FDA issued over 100 warning letters to drugmakers and online prescribing companies, including Hims & Hers, which has developed a multibillion-dollar business around lower-cost obesity medications [2][9]. - Hims & Hers received a warning to remove misleading promotional statements from its website, specifically claims that their products contain the same active ingredients as FDA-approved drugs like Wegovy and Ozempic [3][4]. Company Responses - Hims stated it looks forward to engaging with the FDA and emphasized that its materials indicate compounded treatments are not FDA-approved [4]. - The company has faced scrutiny for its advertising practices, including a Super Bowl ad that failed to disclose side effects of its weight-loss medications [7][9]. Industry Context - The FDA's recent actions mark a shift towards more direct regulation of online platforms, which have previously argued they are not bound by traditional drug advertising rules [4][6]. - The FDA has determined that GLP-1 drugs no longer meet the criteria for shortage, which impacts the compounding practices of companies like Hims [8]. Market Impact - Following the FDA's warning letters, shares of Hims & Hers Health Inc. fell by more than 6.47% [9].

当地时间周二，全球投资者静待美国对等关税揭晓，美股三大指数在交易时间段反复震荡，收盘涨跌不一。截 至收盘，道指0.03%，纳指涨0.87%，标普500指数涨0.38%。 当地时间4月1日，2025福布斯全球亿万富豪榜正式发布，马斯克以3420亿美元的身家登顶。过去一年，他的财 富增加了1470亿美元。当日，特斯拉股价开盘后一路走强，随后在高位震荡。截至收盘，特斯拉收涨3.59%， 报268.46美元/股。 上市次日，媒体公司Newsmax延续涨势，单日涨幅超179%，两日大涨超2230%，市值增加192亿美元至300亿 美元左右，超过老牌媒体股福克斯。分析认为，当前市场缺乏强有力新热点，Newsmax作为发行价低、体量小 的小盘新股，市值相对较小，更容易吸引短线资金炒作，但从以往美股"妖股"表现来看，投资者仍需警惕 Newsmax股价快速拉涨后出现暴跌。 美股三大指数涨跌不一 美国对等关税揭晓前夕，美股上演"过山车"行情，三大指数在交易时间段反复震荡。截至收盘，道指跌11.80 点，跌幅0.03%，报41989.96点；纳指涨150.60点，涨幅0.87%，报17449.89点；标普500指数涨21.22点， ...